ReviewFrontiers in pharmacology2024
Pharmacological and mechanistic aspects of quercetin in osteoporosis.
Review in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review: Quercetin-Secondary Metabolite of the Flavonol Class, with Multiple Health Benefits and Low Bioavailability.International journal of molecular sciences · 2024Pooled it
- A microbiota-substrate-metabolite-target network suggests AKT1-associated links between gut microbiota-derived metabolites and osteoporosis.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Knockdown of MEPE Promotes Cranial Defect Repair and Activates the cAMP/PKA Signaling Pathway.Biochemical genetics · 2026Article
- Network pharmacology-guided discovery of quercetin as an anti-osteoporotic agent from cyathulae radix with dual pro-osteogenic and antioxidant effects.Molecular biology reports · 2026Article
- Quercetin-loaded composite materials for bone regeneration: a review of carriers, controlled release, and mechanistic advances.Stem cell research & therapy · 2026Review
- Development of injectable cuttlebone derived nanohydroxyapatite hydrogel for osteoblast cell encapsulation.Biochemistry and biophysics reports · 2025Article
- Sirtuin 5-mediated desuccinylation of Slc25a4 inhibits osteoporosis by enhancing mitochondrial respiration.Bone research · 2025Article
- Osteoporosis: molecular pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Evaluation of bone regenerative potential of sticky bone combined with DPBM and APRF in a rabbit tibial model: an in vivo study.BMC oral health · 2025Article
- Orally administered degradable nanoarmor-assisted probiotics for remodeling the gut microenvironment and treating osteoporosis.Journal of nanobiotechnology · 2025Article
- Efficacy of 12-month romosozumab monotherapy or combination with eldecalcitol in patients with osteoporosis with and without chronic kidney disease: A real-world retrospective study.Biomedical reports · 2025Article
- KDM3A controls postnatal hippocampal neurogenesis via dual regulation of the Wnt/β-catenin signaling pathway.Cell death and differentiation · 2025Article
- The Role of Senolytics in Osteoporosis.Biomolecules · 2025Review
- Cadmium Inhibits Proliferation of Human Bronchial Epithelial BEAS-2B Cells Through Inducing Ferroptosis via Targeted Regulation of the Nrf2/SLC7A11/GPX4 Pathway.International journal of molecular sciences · 2025Article
- Feeding the cosmos: tackling personalized space nutrition and the leaky gut challenge.NPJ microgravity · 2025Article
- Quercetin Can Alleviate ETECK88-Induced Oxidative Stress in Weaned Piglets by Inhibiting Quorum-Sensing Signal Molecule Autoinducer-2 Production in the Cecum.Antioxidants (Basel, Switzerland) · 2025Article
- Advancements in Antimicrobial Surface Coatings Using Metal/Metaloxide Nanoparticles, Antibiotics, and Phytochemicals.Nanomaterials (Basel, Switzerland) · 2025Review
- Investigation of the molecular mechanism of quercetin in inhibiting ankylosing spondylitis ossification via the bone morphogenetic protein/smad signaling pathway.Medical molecular morphology · 2025Article
- Epimedium brevicornum Maxim alleviates diabetes osteoporosis by regulating AGE-RAGE signaling pathway.Molecular medicine (Cambridge, Mass.) · 2025Article
- Bioactive Compounds from Propolis on Bone Homeostasis: A Narrative Review.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis (OP) is a bone disease associated with increasing age. Currently, the most common medications used to treat OP are anabolic agents, anti-resorptive agents, and medications with other mechanisms of action. However, many of these medications have unfavorable adverse effects or are not intended for long-term use, potentially exerting a severe negative impact on a patient's life and career and placing a heavy burden on families and society. There is an urgent need to find new drugs that can replace these and have fewer adverse effects. Quercetin (Que) is a common flavonol in nature. Numerous studies have examined the therapeutic applications of Que. However, a comprehensive review of the anti-osteoporotic effects of Que has not yet been conducted. This review aimed to describe the recent studies on the anti-osteoporotic effects of Que, including its biological, pharmacological, pharmacokinetic, and toxicological properties. The outcomes demonstrated that Que could enhance OP by increasing osteoblast differentiation and activity and reducing osteoclast differentiation and activity via the pathways of Wnt/β-catenin, BMP/SMAD/RUNX2, OPG/RANKL/RANK, ERK/JNK, oxidative stress, apoptosis, and transcription factors. Thus, Que is a promising novel drug for the treatment of OP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.